Customized GalNAc-conjugated LNP development services for hepatocyte-targeted RNA delivery, ASGPR-mediated uptake studies, ligand density optimization, and liver-oriented formulation screening.
GalNAc-conjugated LNPs are lipid nanoparticles engineered with N-acetylgalactosamine ligands on the surface to support ASGPR-mediated hepatocyte targeting. Developing an effective GalNAc-LNP requires careful design of the GalNAc ligand, including its valency, PEG spacer, lipid anchor, and conjugation method. These choices must then be matched with LNP formulation, surface ligand density, RNA encapsulation, and particle stability to ensure that the ligand remains accessible and the payload can be delivered efficiently. BOC Sciences helps pharmaceutical and biotechnology researchers design, optimize, and characterize GalNAc-displaying lipid nanoparticles for siRNA, mRNA, reporter RNA, guide RNA/mRNA combinations, and other nucleic acid payloads used in liver-targeted delivery research.
GalNAc Ligand Linked Lipid Nanoparticle DiagramWe help researchers develop GalNAc-modified lipid nanoparticles (LNPs) for liver-targeted nanoparticle delivery. Our services cover the full workflow from GalNAc ligand selection and LNP surface modification to formulation optimization, payload loading, physicochemical characterization, and hepatocyte-targeted delivery evaluation. These GalNAc-LNP systems can support disease-related research, mechanism studies, and other liver-oriented delivery applications.
BOC Sciences develops GalNAc ligand components with tunable valency, spacer length, and lipid anchoring structures for targeted LNP formulation. We support the screening and custom synthesis of GalNAc-bearing molecules designed to improve ASGPR recognition, surface exposure, and compatibility with hepatocyte-targeted LNP systems.
We introduce GalNAc ligands onto LNP surfaces through formulation-compatible modification strategies, including pre-formulation incorporation, post-insertion, and surface coupling. Each approach is selected according to payload type, target ligand density, LNP composition, and the desired balance between receptor accessibility and particle stability.
BOC Sciences characterizes GalNAc-conjugated LNPs to confirm ligand incorporation, particle quality, payload retention, and formulation consistency. These data help researchers compare GalNAc-LNP candidates and understand whether surface modification affects nanoparticle stability or delivery-related properties.
We evaluate whether GalNAc modification improves hepatocyte-relevant uptake and delivery performance compared with unmodified LNP controls. Targeting validation can combine cell-based uptake studies, ASGPR-oriented comparison designs, and liver-oriented distribution assessment in suitable research models.
GalNAc-LNP development requires both ligand engineering and nanoparticle formulation control. BOC Sciences supports GalNAc ligand design, surface display optimization, LNP preparation, physicochemical analysis, and biological function evaluation to help researchers build more reliable GalNAc-conjugated LNP systems.
Develop GalNAc-conjugated LNPs with optimized ligand presentation, RNA encapsulation, particle attributes, and ASGPR-oriented hepatocyte delivery performance.
BOC Sciences supports GalNAc-modified LNP development for a wide range of payloads used in liver-oriented nanoparticle delivery research. Different payloads require different loading strategies, surface modification methods, stability controls, and biological evaluation designs. We help researchers match GalNAc ligand presentation with payload properties, LNP formulation, and hepatocyte-targeted delivery requirements.
| Payload Type | Supported Uses & GalNAc-LNP Development Considerations | Request Information |
|---|---|---|
| GalNAc-LNP Development for siRNA | Suitable for hepatocyte-relevant gene-silencing research. GalNAc-LNP development focuses on siRNA encapsulation, free RNA reduction, particle size control, GalNAc ligand density, ASGPR-oriented uptake, and comparative knockdown evaluation in suitable in vitro models. | Inquiry |
| GalNAc-LNP Development for mRNA and Reporter RNA | Designed for reporter expression, protein expression, and formulation comparison studies. Development considers mRNA integrity, encapsulation efficiency, buffer compatibility, particle stability, GalNAc surface exposure, and expression readouts in hepatocyte-relevant systems. | Inquiry |
| GalNAc-LNP Development for gRNA/mRNA Combination | Applicable to co-loaded nucleic acid systems such as guide RNA/mRNA combinations. Formulation development focuses on payload ratio control, co-encapsulation behavior, particle uniformity, GalNAc-lipid compatibility, and cell-based functional evaluation under matched control conditions. | Inquiry |
| GalNAc-LNP Development for ASO and Oligonucleotides | Supports oligonucleotide payloads that require LNP-based protection, formulation comparison, or liver-oriented uptake exploration. We consider oligonucleotide length, backbone chemistry, charge behavior, payload retention, surface ligand density, and separation of free versus particle-associated material. | Inquiry |
| GalNAc-LNP Development for Protein and Peptide | Suitable for enzymes, protein antigens, peptide-like molecules, binding proteins, and functional protein payloads used in liver-oriented delivery research. GalNAc-LNP development focuses on mild loading conditions, aggregation control, activity retention, surface adsorption reduction, and payload-compatible purification. | Inquiry |
| GalNAc-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecule payloads that may benefit from liver-oriented LNP delivery. Development considers drug-lipid compatibility, loading method, leakage control, particle stability, GalNAc surface modification, and payload release behavior. | Inquiry |
| GalNAc-LNP Development for Imaging and Tracking | Supports fluorescent dyes, labeled nucleic acids, labeled proteins, and other tracking payloads used to study GalNAc-LNP uptake, localization, biodistribution trends, and formulation comparison. We optimize labeling compatibility, signal retention, particle quality, and GalNAc-dependent uptake evaluation. | Inquiry |
| GalNAc-LNP Development for Custom Payload | Developed for projects involving multiple payloads, unusual molecular formats, or early feasibility testing. BOC Sciences can evaluate payload compatibility, loading sequence, GalNAc modification method, formulation stability, and hepatocyte-targeted delivery performance to identify practical development routes. | Inquiry |
Successful GalNAc-LNP development requires the right ligand design, stable particle formulation, efficient payload loading, and clear targeting evaluation. BOC Sciences helps optimize these steps together to improve hepatocyte-targeted delivery performance.
✔ Weak Hepatocyte Uptake Improvement
A GalNAc-modified LNP may show limited uptake improvement when the ligand is shielded by PEG, displayed at an unsuitable density, or positioned too close to the particle surface. We screen GalNAc-lipid structure, spacer length, ligand density, and PEG-lipid ratio to improve receptor-accessible presentation.
✔ Particle Size Increase After GalNAc Modification
GalNAc-lipid incorporation can disturb LNP self-assembly, leading to larger particles or broad PDI. We rebalance helper lipid, cholesterol, PEG-lipid, and GalNAc-lipid levels while adjusting microfluidic mixing conditions to restore particle uniformity.
✔ Reduced RNA Encapsulation Efficiency
Surface-modified formulations may alter the electrostatic and self-assembly environment required for nucleic acid loading. We optimize ionizable lipid content, N/P-related variables, aqueous phase pH, and payload input conditions for nucleic acids encapsulation in LNPs.
✔ Ligand Density and Stability Conflict
Higher GalNAc density may improve receptor recognition in some systems, but excessive surface modification can increase aggregation, alter zeta potential, or reduce storage stability. We select candidates based on combined particle, payload, and cell-readout data rather than ligand density alone.
✔ Unclear ASGPR-Related Delivery Contribution
Uptake data can be difficult to interpret without proper controls. We prepare matched unmodified LNPs, GalNAc-modified LNPs, and formulation variants to help clients distinguish general LNP uptake from GalNAc-associated hepatocyte interaction.
✔ Poor Expression or Gene-Silencing Readout
Efficient uptake does not always translate into productive RNA delivery. We evaluate formulation variables connected to endosomal release, RNA integrity, and functional delivery, with optional support from LNP endosomal escape evaluation.
BOC Sciences helps research teams troubleshoot GalNAc ligand presentation, RNA loading, particle instability, hepatocyte uptake, and functional delivery readouts through data-guided LNP formulation development.
The project begins with a clear discussion of your delivery goal, payload type, target hepatocyte model, desired readout, and expected LNP attributes. We also review your preferences for GalNAc ligand structure, lipid anchor, payload concentration, and evaluation method. Based on these details, BOC Sciences prepares a practical GalNAc-LNP development plan for your review and confirmation.
After the project scope is confirmed, we design a GalNAc surface strategy that fits your payload and targeting objective. The design may include GalNAc valency selection, PEG spacer optimization, lipid anchor selection, conjugation method selection, and surface modification route planning. We also define a suitable GalNAc density range to support ASGPR recognition while maintaining LNP stability.
BOC Sciences prepares GalNAc-modified LNP candidates using suitable methods such as premixing, post-insertion, or surface coupling. During formulation optimization, we adjust lipid composition, payload loading, mixing conditions, buffer exchange, and particle stability. When needed, unmodified LNP controls are also prepared to help you compare the effect of GalNAc modification.
Each GalNAc-LNP candidate is evaluated for particle size, PDI, zeta potential, payload loading, surface GalNAc density, and formulation integrity. We can also support hepatocyte-targeted delivery evaluation through suitable in vitro uptake, binding, expression, activity, or biodistribution-related readouts. The final report helps you compare formulation candidates and select a practical direction for the next stage of research.
Challenge: A biotechnology research team was developing a GalNAc-modified siRNA LNP for a hepatocyte-expressed transcript. Their first formulation used a fixed GalNAc-lipid level and produced particles around 125-170 nm with PDI values often above 0.25. Compared with the unmodified LNP control, hepatocyte uptake increased only slightly, and gene-silencing readouts varied widely between cell experiments.
Diagnosis: The formulation showed two connected issues. First, the GalNAc ligand was likely being partially shielded by the PEG layer, reducing receptor-accessible ligand display. Second, increasing GalNAc-lipid content without rebalancing PEG-lipid and helper lipid ratios caused broader particle distribution, making uptake data difficult to interpret.
Solution: BOC Sciences designed a formulation screen covering four GalNAc-lipid levels, two PEG-lipid ratios, two spacer designs, and three lipid-to-siRNA input ratios. Matched unmodified LNP controls were prepared under the same microfluidic conditions. Candidate samples were evaluated by DLS, zeta potential, siRNA encapsulation analysis, free siRNA assessment, and hepatocyte-model uptake testing. Formulations with high GalNAc density but PDI above 0.25 were rejected even when uptake signal appeared higher, because the particle data suggested unstable performance.
Result: The selected formulation used a moderate GalNAc-lipid density and a reduced PEG-shielding condition. It produced particles around 85-115 nm with PDI below 0.20 across repeated preparations. Encapsulated siRNA was above 80% based on total/free RNA comparison, and the hepatocyte uptake signal increased approximately 2.3-fold relative to the matched unmodified LNP control. The client obtained a more interpretable formulation set for downstream gene-silencing comparison.
Challenge: A research group working with a 1.9 kb reporter mRNA wanted to evaluate GalNAc-LNP delivery in an ASGPR-positive hepatocyte model. Their initial GalNAc-modified formulation showed acceptable mRNA encapsulation, but particle size increased from approximately 95 nm to more than 180 nm after short storage, and reporter expression varied significantly between batches.
Diagnosis: The added GalNAc-lipid changed the surface packing behavior of the original mRNA LNP. The previous ionizable lipid and helper lipid ratio was suitable for the unmodified LNP, but not for the GalNAc-displaying version. The formulation also used a high total lipid concentration during mixing, which increased the risk of particle fusion after buffer exchange.
Solution: BOC Sciences redesigned the formulation matrix by adjusting ionizable lipid content, helper lipid ratio, cholesterol level, GalNAc-lipid density, and total lipid concentration. We compared two flow rate ratios, three total flow rates, and two post-formulation buffer exchange conditions. Candidate LNPs were assessed for particle size, PDI, zeta potential, mRNA encapsulation, mRNA integrity, and reporter expression in in vitro hepatocyte-relevant evaluation.
Result: The optimized GalNAc-mRNA LNP maintained an average size of 90-125 nm with PDI below 0.22 after buffer exchange. mRNA encapsulation remained above 75%, and reporter expression became more consistent across three preparation runs. Compared with the starting GalNAc-LNP formulation, the selected candidate showed improved particle stability and a clearer expression difference versus the unmodified LNP control.
Extensive LNP Development ExperienceBOC Sciences has practical experience in LNP formulation, payload loading, surface modification, and particle characterization. This experience helps clients develop GalNAc-modified LNPs with improved formulation quality, stability, and targeting performance.
Strong GalNAc Surface Engineering CapabilityWe support GalNAc ligand selection, PEG spacer design, lipid anchor selection, ligand-lipid conjugation, and surface density optimization. These capabilities help improve GalNAc exposure, ASGPR recognition, and hepatocyte-targeted delivery.
Payload-Compatible Formulation DesignDifferent payloads require different GalNAc-LNP strategies. BOC Sciences designs formulations according to payload properties, including nucleic acids, proteins, peptides, small molecules, imaging agents, and customized payload systems.
Integrated Characterization and Targeting EvaluationOur services combine particle size analysis, PDI measurement, zeta potential testing, payload loading analysis, surface GalNAc density evaluation, and hepatocyte-targeted delivery assessment. These data help clients compare candidates and select better formulations.
Flexible Support for Custom GalNAc-LNP ProjectsBOC Sciences supports feasibility testing, formulation screening, surface modification optimization, control LNP preparation, and targeting validation. The service scope can be adjusted according to each client's project goal, payload type, and evaluation needs.
GalNAc-conjugated lipid nanoparticles are mainly designed for hepatocyte-oriented delivery because GalNAc can bind the asialoglycoprotein receptor, or ASGPR, which is highly expressed on hepatocytes. This receptor-recognition mechanism gives GalNAc-LNPs a clearer liver-cell targeting logic than conventional LNPs that rely heavily on passive liver accumulation or ApoE-related uptake pathways. For drug development researchers, this makes GalNAc-LNPs valuable for delivering siRNA, mRNA, antisense oligonucleotides, gene-editing components, reporter RNA, and other payloads into liver-related cell models. However, effective targeting depends on GalNAc density, linker length, lipid anchor selection, PEG shielding, and the core LNP formulation.
GalNAc improves LNP delivery by adding a receptor-recognition layer to the nanoparticle surface. When properly displayed, GalNAc ligands can interact with ASGPR on hepatocytes and promote receptor-mediated cellular uptake. This can help researchers improve liver-cell selectivity and reduce dependence on non-specific nanoparticle uptake. However, GalNAc modification alone does not guarantee strong payload function. The LNP must still maintain suitable particle size, narrow PDI, strong payload encapsulation, colloidal stability, and effective endosomal release. BOC Sciences supports GalNAc-LNP development by screening ligand density, PEG spacer design, lipid composition, and payload-compatible formulation conditions to identify candidates with both improved uptake and functional delivery performance.
GalNAc-LNPs can be developed for many payload types used in liver-focused drug delivery research. Common payloads include siRNA, mRNA, self-amplifying RNA, circular RNA, antisense oligonucleotides, gRNA/mRNA combinations, reporter RNA, fluorescent probes, imaging payloads, and selected small molecules. Each payload type requires a different formulation strategy. For example, siRNA projects usually focus on encapsulation efficiency, free RNA reduction, and gene-silencing readouts, while mRNA projects require stronger attention to RNA integrity, expression level, and intracellular release. For co-loaded systems, payload ratio and co-encapsulation behavior are especially important. GalNAc conjugation must be optimized together with the LNP core to avoid reduced loading, particle growth, or weak functional activity.
GalNAc-LNP targeting should be validated through both uptake assays and functional payload readouts. A strong study design usually compares unmodified LNPs, GalNAc-LNPs with different ligand densities, and receptor-competition or ASGPR-different cell models. Common evaluation methods include particle size analysis, PDI measurement, zeta potential testing, payload encapsulation analysis, GalNAc surface-density assessment, flow cytometry, confocal imaging, intracellular localization studies, reporter expression, siRNA knockdown, or gene-editing activity. Uptake data alone may be misleading because nanoparticles can enter cells through several pathways. A useful GalNAc-LNP candidate should show not only improved hepatocyte-related uptake, but also measurable payload function under matched experimental conditions.
The main challenge in GalNAc-LNP development is balancing targeting efficiency, particle stability, and payload function. Low GalNAc density may not provide enough ASGPR interaction, while excessive ligand density can disturb LNP self-assembly, increase particle size, broaden PDI, or reduce storage stability. PEG spacer length is another key factor: a short spacer may hide GalNAc near the particle surface, while a long spacer may increase surface shielding and reduce productive uptake. In some projects, researchers observe strong cellular uptake but weak mRNA expression or siRNA knockdown, suggesting that endosomal escape or payload integrity is the true bottleneck. BOC Sciences helps address these issues through formulation screening, ligand-density optimization, characterization, and cell-based functional evaluation.
